Open AccessOutcome of childhood acute lymphoblastic leukemia treatment in a single center in Brazil: A survival analysis study
Author(s) -
Bonilha Thais A.,
Obadia Danielle D. A.,
Valveson Andressa C.,
Land Marcelo G. P.
Publication year - 2022
Publication title -
cancer reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 5
ISSN - 2573-8348
DOI - 10.1002/cnr2.1452
Subject(s) - medicine , asparaginase , proportional hazards model , multivariate analysis , cohort , lymphoblastic leukemia , survival analysis , retrospective cohort study , log rank test , leukemia , pediatrics
Background Acute lymphoblastic leukemia (ALL) is the most common neoplasm in childhood. The probability of current overall survival (OS) is around 90% in developed countries. There are few studies that demonstrate the results in Brazil. Aim This work aims to analyze the results of children with ALL treated at a single institution in Rio de Janeiro. Methods and results Retrospective analysis survival study of a cohort of childhood ALL patients treated in Hemorio. Kaplan–Meier and log‐rank methods were used for the analysis of OS and events‐free survival (EFS) and the Cox proportional hazards regression model for multivariate analysis. The probability of OS and EFS at 6 years was 52% and 45%. The probability of OS and EFS in 6 years for patients aged 10‐17 years was 31% and 28% and for the younger was 65% and 55%, respectively ( p < .001). A probability of OS and EFS in 6 years for patients with more than 100 000 leukocytes/mm 3 at diagnosis was 19% and 16% and those with less than 100 000 were 62% ( p = .007) and 55% ( p = .008). Those who received less than 10 doses of native Escherichia coli asparaginase had a probability of OS and EFS in 6 years of 27% and 21% and those who received at least 10 doses were 74% and 65% ( p < .001). Conclusions The presence of a high number of adolescents and high‐risk patients, as well as many patients who discontinued the use of asparaginase or any substitute led to a lower probability of OS and EFS in our cohort.